Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03979131 | Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)(MONEO) | active not recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04898504 | HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.(EXCALIBUR1+2) | active not recruiting | Phase 2 | 45 | Oslo University Hospital |
| 1 |
| Nov 7, 2024 |
| clinicaltrials |
| NCT05595473 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma | active not recruiting | Phase 1 / Phase 2 | 42 | Rznomics, Inc.OTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05674422 | GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.(REVEAL) | active not recruiting | — | 120 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06667050 | CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer | active not recruiting | Phase 2 | 58 | West China HospitalOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06662643 | A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection(STAR-TAR) | active not recruiting | N/A | 110 | Zhongnan HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04161092 | The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases(SOULMATE) | active not recruiting | N/A | 45 | Vastra Gotaland RegionOTHER_GOV | 1 | Oct 28, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE) | active not recruiting | Phase 3 | 419 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05659914 | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | active not recruiting | Phase 2 | 40 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06641700 | Predictive Value of Air Pollution and Metabolomics for Gastric Cancer. | active not recruiting | — | 200 | Dong PengOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643429 | Impact of Environmental Factors and Metabolomics on Colorectal Cancer. | active not recruiting | — | 700 | Dong PengOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06640153 | MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma | active not recruiting | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06632106 | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | active not recruiting | — | 97 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614660 | Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer | active not recruiting | — | 800 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614699 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients | active not recruiting | — | 8,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05656326 | Follow-up After Surgery for Colorectal Cancer(FUTURE-primary) | active not recruiting | — | 200 | Erasmus Medical CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05638698 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) | active not recruiting | Phase 2 | 24 | University of Kansas Medical CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06606912 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients | active not recruiting | — | 4,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04515615 | Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) | active not recruiting | Phase 2 | 52 | Yu jirenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05953181 | Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer(SANO) | active not recruiting | N/A | 776 | Erasmus Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06540261 | The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | active not recruiting | Phase 1 | 65 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601985 | Exploring the Effect of Colonic J-pouch in Anorectal Preservation Surgery for Ultra-low Rectal Cancer. | active not recruiting | — | 154 | Shanghai 10th People's HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT06547385 | Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer | active not recruiting | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04554771 | Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy(BASALT) | active not recruiting | Phase 2 | 41 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06524466 | Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06490107 | Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06138769 | Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma | active not recruiting | Phase 2 | 50 | Asan Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06342167 | Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT06429904 | Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 31 | Peking Union Medical College HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03306901 | Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma(ASSURE) | active not recruiting | N/A | 240 | Samsung Medical CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04878783 | Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG | active not recruiting | — | 138 | University of Roma La SapienzaOTHER | 2 | May 9, 2024 | clinicaltrials |
| NCT03351296 | Two Chemotherapy Regimens Plus or Minus Bevacizumab(BETTER2) | active not recruiting | Phase 2 | 140 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT02931890 | Multicentric Randomised Trial for Resectable Gastric Cancer(CRITICS-II) | active not recruiting | Phase 2 | 207 | The Netherlands Cancer InstituteOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06379334 | Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population | active not recruiting | — | 180 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03464305 | ASPIRIN Trial Belgium(ASPIRIN) | active not recruiting | Phase 3 | 148 | University Hospital, AntwerpOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients(ASPIRIN) | active not recruiting | Phase 3 | 770 | Leiden UniversityOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06315361 | DIAbetes and NAFLD(DIANA) | active not recruiting | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05219734 | MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment(MARIA) | active not recruiting | — | 400 | Invitae CorporationINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05222854 | Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma" | active not recruiting | — | 200 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT03950271 | SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 25 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03413254 | Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases(COLOPEC-II) | active not recruiting | Phase 3 | 389 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2024source: clinicaltrials